Practical use of apomorphine infusion in Parkinson's disease: lessons from the TOLEDO study and clinical experience.
Apomorphine infusion
Clinical practice
Parkinson’s disease
Journal
Journal of neural transmission (Vienna, Austria : 1996)
ISSN: 1435-1463
Titre abrégé: J Neural Transm (Vienna)
Pays: Austria
ID NLM: 9702341
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
31
07
2023
accepted:
15
08
2023
medline:
15
11
2023
pubmed:
2
9
2023
entrez:
1
9
2023
Statut:
ppublish
Résumé
Subcutaneous apomorphine infusion is a device-aided therapy for Parkinson's disease that can be considered when motor fluctuations become persistent and are no longer adequately controlled by oral/transdermal medication. Apomorphine infusion is less invasive than enteral levodopa, deep brain stimulation or focused ultrasound, and is often indicated even when neurosurgical approaches are contraindicated. This article aims to provide practical guidance for doctors and nurses initiating and treating patients with apomorphine infusion, and is based on both trial data and clinical experience from movement disorders specialists. A post hoc analysis of data from the TOLEDO randomized clinical trial of apomorphine infusion was conducted along with an analysis of 'real world' experience from 13 movement disorders specialists using a questionnaire that focused on starting patients on apomorphine infusion. Practical guidelines for starting treatment with apomorphine infusion are provided taking into consideration the regional disparities in healthcare. Apomorphine infusion is straightforward to administer but to be successful it requires concordance from the patient and family, and clinical support from an experienced team of doctors and nurses, particularly in the early months of treatment.
Identifiants
pubmed: 37658155
doi: 10.1007/s00702-023-02686-7
pii: 10.1007/s00702-023-02686-7
pmc: PMC10645621
doi:
Substances chimiques
Apomorphine
N21FAR7B4S
Antiparkinson Agents
0
Levodopa
46627O600J
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1475-1484Informations de copyright
© 2023. The Author(s).
Références
Drugs R D. 2018 Jun;18(2):91-107
pubmed: 29546602
Clin Neuropharmacol. 2019 Sep/Oct;42(5):172-178
pubmed: 31567642
Parkinsonism Relat Disord. 2021 Oct;91:146-151
pubmed: 34624769
J Neurol. 2017 May;264(5):946-954
pubmed: 28364292
J Pers Med. 2021 Jun 08;11(6):
pubmed: 34201198
Clin Neuropharmacol. 2015 Jul-Aug;38(4):132-4
pubmed: 26166238
Br J Clin Pharmacol. 2016 Aug;82(2):461-72
pubmed: 27062307
J Clin Gastroenterol. 2019 Oct;53(9):648-652
pubmed: 30720577
J Neural Transm (Vienna). 2022 Sep;129(9):1169-1178
pubmed: 34324057
J Neurol. 2016 Jun;263(6):1111-9
pubmed: 27060084
Clin Drug Investig. 2018 Apr;38(4):287-312
pubmed: 29327219
Parkinsonism Relat Disord. 2016 Dec;33 Suppl 1:S42-S48
pubmed: 27919586
Parkinsonism Relat Disord. 2016 Dec;33 Suppl 1:S13-S21
pubmed: 27979722
NPJ Parkinsons Dis. 2021 Jun 11;7(1):50
pubmed: 34117268
J Neurol Sci. 2018 Dec 15;395:113-118
pubmed: 30312901
Br J Clin Pharmacol. 2021 Oct;87(10):3649-3658
pubmed: 33439512
Synapse. 2015 Apr;69(4):183-9
pubmed: 25645960
Lancet Neurol. 2022 May;21(5):428-437
pubmed: 35429481
J Neurol Sci. 2017 Mar 15;374:53-55
pubmed: 28104232
Mov Disord. 2005 Feb;20(2):151-7
pubmed: 15390035
Mov Disord. 2000 Sep;15(5):789-94
pubmed: 11009181
Parkinsonism Relat Disord. 2021 Feb;83:79-85
pubmed: 33486139
Lancet Neurol. 2018 Sep;17(9):749-759
pubmed: 30055903
Parkinsonism Relat Disord. 2016 Feb;23:17-22
pubmed: 26709292
Parkinsonism Relat Disord. 2010 Jan;16(1):71-2
pubmed: 19524477
Parkinsonism Relat Disord. 2016 Dec;33 Suppl 1:S49-S55
pubmed: 27939324
Mov Disord. 2008 Jun 15;23(8):1130-6
pubmed: 18442107
Mov Disord. 2002 Nov;17(6):1235-41
pubmed: 12465062
Parkinsonism Relat Disord. 2016 Dec;33 Suppl 1:S2-S8
pubmed: 27932224
Mov Disord. 2018 Aug;33(8):1248-1266
pubmed: 29570866